1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Tecentriq Data Builds As IMpower132 In NSCLC Meets PFS Co-Primary Endpoint

 
• By Sten Stovall

As Roche keeps building its catalog of positive Tecentriq results, its Phase III IMpower132 study meets PFS endpoint in NSCLC, with OS data coming later.

Xray
Roche's IMpower132 Tecentriq Combo Trial Is Positive In NSCLC • Source: Shutterstock

Prospects for Roche's cancer immunotherapy Tecentriq (atezolizumab) have been boosted again, this time from the Phase III IMpower132 trial which met its co-primary endpoint of progression free survival (PFS) and showed the drug, when combined with Alimta (pemetrexed) and chemotherapy, produced a statistically significant reduction in the risk of disease worsening or death in first-line non-small cell lung cancer (NSCLC) in an all-comer population.

Roche when announcing the data on July 19 said IMpower132's co-primary endpoint of overall survival (OS) had not yet matured...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Clinical Trials

MBX Surges As Phase II Data Show Competitive Profile For Canvuparatide

 
• By Mandy Jackson

MBX Biosciences reported Phase II results for once-weekly canvuparatide that showed comparable efficacy to Ascendis Pharma’s once-daily Yorvipath for hypoparathyroidism.

Ionis Targets Ultra-Rare Disease Market With Zilganersen

 
• By Alaric DeArment

The biotech announced positive topline results from its pivotal study in Alexander disease, which has an estimated population of about 300 in the US.

EADV: UCB’s Bimzelx Primed To Maintain Pole Position in HS

 
• By Kevin Grogan

The Belgium-based group has collected heaps of long-term efficacy and safety data which will help stave off the competition.

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

More from R&D

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 
• By Alexandra Shimmings

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

QL Biopharm’s Zovaglutide Offers Potentially Safer Once-Monthly Obesity Option

 
• By Dexter Jie Yan

Zovaglutide tied Amgen’s MariTide in weight reduction at Week 24 in a Phase II study, but with a potentially better safety profile. However, efficacy versus existing once-weekly drugs is a remaining question.